Oncobiologics Priced, Nasdaq: ONS

Developing biosimilars of blockbuster drugs Humira and Avastin.

Industry: Health Care

Latest Trade: $1.29 +0.02 (+1.6%)

First Day Return: -20.0%

Return from IPO: -78.8%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies, or mAbs, in the disease areas of immunology and oncology. A mAb is a type of protein that is produced by a single clone of cells or cell line and made to bind to a specific substance in the body. Our strategy is to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company. We have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our BioSymphony Platform. We believe this platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mAb biosimilars and was designed to provide significant pricing flexibility. Since inception, we have advanced two product candidates into clinical trials: ONS-3010, a Phase 3-ready biosimilar to adalimumab (Humira), and ONS-1045, a Phase 3-ready biosimilar to bevacizumab (Avastin). Additionally, we have identified multiple other biosimilar product candidates, including six that are in active preclinical development, one of which is expected to be ready to enter clinical trials in 2016.
more less
IPO News for Oncobiologics
more
IPO Data
IPO File Date 01/15/2016
Offer Price $6.00
Price Range $6.00 - $6.00
Offer Shares (mm) 5.8
Deal Size ($mm) $35
IPO Data
IPO Date 05/12/2016
Offer Price $6.00
Price Range $6.00 - $6.00
Offer Shares (mm) 5.8
Deal Size ($mm) $35
Underwriters
more
Company Data
Headquarters Cranbury, NJ
Founded 2010
Employees 89
Website www.oncobiologics.com